Lenvatinib Plus PD-1 Inhibitors versus Regorafenib in Patients with Advanced Hepatocellular Carcinoma After the Failure of Sorafenib: A Retrospective Study

Xu Y, Fu S, Liu K, Mao Y, Wu J

Therapeutics and Clinical Risk Management 2023, 19:853-863

Published Date: 24 October 2023